Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.

Authors

Aarti K. Bhatia

Yale School of Medicine & Yale Cancer Center, New Haven, CT

Aarti K. Bhatia , Ranee Mehra , Saad A. Khan , Brian L. Egleston , R. Katherine Alpaugh , Miriam Lango , John A. Ridge , Barbara Burtness

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

First Author: Makoto Tahara

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.

First Author: Erminia Massarelli

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.

First Author: Douglas Adkins

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors.

First Author: Majd Issa